Antibodies News and Research

RSS

NHS Blood and Transplant now offers more detailed blood testing for patients with haemoglobinopathies

Patients with blood disorders can now get detailed blood group typing to enable better matched and potentially safer transfusions.

25 Jan 2016

Biomedical innovation in the UK: an interview with Zahid Latif

The biomedical research base is one of the UK's strengths; over 1500 companies in the Pharmaceuticals and biotechnology area are established in the UK employing over 70,000.

22 Jan 2016

Simple & Efficient Protocol for Native Chromatin Immunoprecipitation

Chromatrap, a business unit of Porvair Sciences, announces a new patented protocol that is able to simply, quickly and efficiently enrich transcription factors from Native Chromatin.

From Chromatrap® - Porvair Sciences Ltd 22 Jan 2016

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system's potential to fight cancer.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Only 17.4 percent of ambulatory care nurses reported compliance in all nine standard precautions for infection prevention, according to a study published in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

21 Jan 2016

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Colorado State University's Biopharmaceutical Manufacturing and Academic Resource Center has been awarded a 10-month, $4.6 million contract funded by the Department of Defense to help develop and manufacture new vaccines to fight encephalitic viruses that cause inflammation of the brain.

21 Jan 2016

Automated OpenSPR-XT will accelerate discoveries in protein science

Nicoya Lifesciences, a leader in label-free molecular analysis, announced today its newest product, OpenSPR-XT - a fully automated molecular analysis instrument based on the highly successful OpenSPR instrument.

From Nicoya Lifesciences 20 Jan 2016

Adding naturally-occurring protein to flu vaccine may offer protection to babies

According to the World Health Organization, influenza causes serious illness among millions of people each year, resulting in 250,000 to 500,000 deaths. Those most at risk include infants younger than six months, because they cannot be vaccinated against the disease.

20 Jan 2016

IMP, WEHI scientists successfully characterize central regulator of plasma cell function

Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.

20 Jan 2016

Animal antibodies help identify diseased cells during immunohistology procedures

We all know it from biology lessons at school: Antibodies help us to ward off disease and are essential components of our immune system. What many people do not know is that physicians and scientists use animal antibodies to identify diseased or mutated cells.

20 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

New clinical imaging method may enable doctors to tackle lung infections

A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.

19 Jan 2016

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

According to recently published Pharmaion report, "Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020", the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to cross US$ 3 billion by 2019.

18 Jan 2016

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH's National Institute of Allergy and Infectious Diseases (NIAID).

17 Jan 2016

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever.

13 Jan 2016

Discoveries could lead to development of novel therapies to prevent C. diff infection

Researchers at Vanderbilt University Medical Center have obtained the crystal structure of a toxin from the bacterium Clostridium difficile ("C. diff") -- the leading cause of hospital-acquired diarrhea in the United States.

12 Jan 2016

MD Anderson signs collaborative research and development agreement with Enumeral

The University of Texas MD Anderson Cancer Center today announced that it has entered into a collaborative research and development agreement with Enumeral Biomedical Holdings Inc.

12 Jan 2016

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.

11 Jan 2016

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

F-star today announced that it has entered into a collaboration and license agreement with AbbVie to research and develop bispecific antibodies in immuno-oncology. Financial terms were not disclosed.

11 Jan 2016

Antibodies News and Research

NHS Blood and Transplant now offers more detailed blood testing for patients with haemoglobinopathies

Biomedical innovation in the UK: an interview with Zahid Latif

Simple & Efficient Protocol for Native Chromatin Immunoprecipitation

MD Anderson and AbbVie join forces to design new immunotherapy cancer patients

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

CSU's BioMARC awarded DoD contract to help develop new vaccines to combat encephalitic viruses

Automated OpenSPR-XT will accelerate discoveries in protein science

Adding naturally-occurring protein to flu vaccine may offer protection to babies

IMP, WEHI scientists successfully characterize central regulator of plasma cell function

Animal antibodies help identify diseased cells during immunohistology procedures

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

New clinical imaging method may enable doctors to tackle lung infections

NSCLC treatments market in Europe expected to cross US$ 3 billion by 2019

Large-scale clinical trial to evaluate dengue vaccine launched in Brazil

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Discoveries could lead to development of novel therapies to prevent C. diff infection

MD Anderson signs collaborative research and development agreement with Enumeral

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

F-star signs agreement with AbbVie to discover, develop bispecific antibodies in immuno-oncology

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo